Huaihua Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is released as an uncoated bulk active pharmaceutical ingredient powder with a multi-route veterinary grade designation. The model is a single crystalline or amorphous powder entity that is not pre-formulated with binders, carriers, preservatives, or pH modifiers. Release documentation reports identification by infrared absorption and HPLC retention time against the pharmacopoeial reference standard, loss on drying by Ph. Eur. 2.2.32, sulfated ash, related substances by a validated liquid chromatographic procedure, residual solvents by Ph. Eur. 5.4, and particle size distribution by laser diffraction under ISO 9276-2. The bulk powder is intended for downstream processing into tablets, capsules, injectable solutions after aseptic or terminal sterilisation, oral powders, granules, medicated premixes, and drinking-water solutions. Because no functional excipients are included, route-specific formulation and validation remain the responsibility of the manufacturing site.

What Distinguishes a Multi-Route Veterinary API Powder from Single-Dosage-Form Intermediates?

A single-dosage-form intermediate is usually optimised for one manufacturing route, such as direct compression or sterile filling, and its particle size, residual moisture, and microbial limits are narrowed to that route. The multi-route grade is controlled across a broader specification window: dry blend uniformity for tablet and capsule production, controlled endotoxin load for parenteral processing, and acceptable wetting for premix and solution compounding. Tablet-grade material may trade flowability for coarse particles, while an injectable lot requires bacterial endotoxins below 0.50 EU/mg and sub-visible particle compliance after reconstitution under Ph. Eur. 2.9.19. The Huaihua product is not equivalent to a feed additive premix; it lacks the granular carrier and anti-caking oil that would simplify farm use but would restrict pharmaceutical processing. The grade also differs from sterile injection API because it is not supplied as a sterile lyophilised cake and therefore cannot be introduced directly into aseptic filling without a prior dissolution and sterilising filtration step.

A release specification matrix for the multi-route grade typically includes the following parameters; exact limits are confirmed against the product-specific certificate of analysis and current pharmacopoeial monographs.

For tablet and capsule manufacturing, the powder is typically pre-blended with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. Dry mixing trials on a 600-L bin blender at 6–8 rpm indicate acceptable content uniformity after 15–20 min when the active substance D50 remains between 10 µm and 45 µm. The Hausner ratio measured under USP <1174> generally falls between 1.18 and 1.34, corresponding to intermediary flow behaviour that may require glidant addition. Direct compression is usually limited to active fractions below 10–15% of tablet mass. At higher drug loads, roller compaction or wet granulation is preferred because the undiluted powder exhibits high ejection force and capping tendency. A D90 above 120 µm increases segregation risk in low-dose formulations, whereas a D10 below 5 µm raises dust exposure and punch sticking.

Controlling Particle Size, Polymorph Stability, and Direct Compression Behavior

Particle size distribution is evaluated on every release lot because it controls dissolution, content uniformity, and segregation. Laser diffraction uses wet dispersion in 0.1% polysorbate 80 solution; the method reports D10, D50, and D90 under ISO 9276-2. Polymorph stability is monitored by differential scanning calorimetry and X-ray powder diffraction, and any conversion detected after milling or drying requires revalidation of the dissolution profile. Direct compression is suitable only when the active load is low and the filler system provides plastic deformation. In a single-station press at 15–25 kN compression force, tablets containing 20% active substance and 80% microcrystalline cellulose have shown acceptable hardness but elevated ejection force when magnesium stearate exceeds 1.0% of the formula. If the D50 drifts above 45 µm, dissolution may slow in neutral aqueous media; if the D10 falls below 5 µm, the powder may require containment and wet granulation to control dust.

Wet granulation of the multi-route powder in a high-shear mixer granulator presents a narrow processing window. In a 300-L vessel, binder addition should be ramped over 120–180 s; rapid hydration of fines can raise impeller torque above 45 N·m and generate oversized agglomerates. Endpoint control by power consumption and probe temperature is recommended, with moisture content of the wet mass held between 8% and 12%. Drying in a fluid bed at 60 °C inlet air until loss on drying is below 1.0% prevents hardening and subsequent capping. If the granulate is over-dried, the D50 may shift upward due to irreversible aggregation, and re-milling may be required to restore tableting performance. This process conflict is less pronounced in low-shear tumble granulation but may require a longer wet massing time of 20–30 min.

Capsule filling on an automatic dosator or tamping-pin machine is more tolerant of marginal flow than tablet compression, but segregation remains a critical risk when the active fraction is below 2% of the fill weight. The powder is usually granulated with a 5% povidone binder solution in a fluid-bed granulator at inlet air temperature 50–60 °C to produce granules with bulk density 0.45–0.55 g/mL. Granules are screened through a 1.0 mm sieve and dried to loss on drying below 1.0%. Fluid-bed top-spray processing reduces fine-particle dust and improves flow into size 3 and size 4 hard gelatin capsules. If the powder is filled without granulation, high fines can cause variable fill weight and powder leakage at the cap-body junction.

For injectable and oral solution dosage forms, the powder is dissolved in purified water or Water for Injection with pH adjustment and tonicity modification as required by the active substance. For parenteral use, the solution is filtered through a 0.22 µm sterilising-grade membrane and filled aseptically; terminal sterilisation is acceptable only when the active molecule remains stable under the selected sterilisation cycle. Bioburden before filtration should be controlled below 10² CFU/100 mL at the filling line. Bacterial endotoxins are tested by Ph. Eur. 2.6.14 on parenteral-grade lots with a limit of ≤ 0.50 EU/mg. Sub-visible particle counts must comply with Ph. Eur. 2.9.19 for containers with nominal volume up to 100 mL. For oral solutions, a preservative system is required when water activity exceeds 0.6 and when the container is multi-dose.

Sterilising filtration throughput is influenced by dissolved solids, viscosity, and residual insoluble particulates from the raw API. In a small-scale pilot line with a 0.22 µm polyethersulfone filter cartridge, flow decay above 30% from the initial flux within 30 min has been observed when the API contains fines below 5 µm or when dissolution pH is not optimised. Prefiltration through a 0.45 µm membrane is therefore used to protect the sterilising filter. The dissolved solution should be held in a stainless-steel vessel with continuous mixing at 100–150 rpm until filling; for oxygen-sensitive actives, nitrogen overlay is required. These handling constraints distinguish the bulk powder from ready-to-use sterile concentrates, which are supplied in sealed single-dose containers with terminal sterilisation completed.

When Drinking-Water Premixes Require Rapid Wetting and Uniform Dispersion

Poultry and swine drinking-water medication requires rapid wetting at water temperatures from 5 °C to 25 °C without foaming, sedimentation, or nozzle blockage. A laboratory wetting test in a 1-L beaker with magnetic stirring at 200 rpm and water temperature 20 °C typically shows complete visual dispersion within 3–5 min for a D50 of 20–30 µm. Water hardness above 250 ppm CaCO₃ can reduce dissolution rate by interacting with acidic or anionic active substances, while alkaline pH above 8.0 may accelerate degradation for base-labile molecules. In feed premixes, geometric dilution is performed in a ribbon mixer: a 1:10 active-to-carrier first dilution for 10–12 min, followed by a second 1:10 dilution to reach the final medicated feed inclusion. Carrier selection should favour ground corn or lactose monohydrate with particle size in the 300–850 µm range to reduce segregation of the fine API.

Medicated powders and granules for oral top-dressing are prepared by adsorption onto silica, lactose, dextrose, or feed-grade carriers. The powder may be granulated by low-shear wet massing or fluid-bed top spray to improve handling and reduce segregation. Granules are dried to moisture below 1.0%, sieved through 1.0 mm, and filled into sachets or bulk containers. In oral solutions, co-solvents such as propylene glycol and glycerin may be required for poorly water-soluble actives; the final pH is adjusted to a target range based on stability and palatability in the target species. The absence of pre-formulated preservative or antioxidant allows flexibility for species-specific formulations but increases the need for in-use stability testing and antimicrobial preservation validation under Ph. Eur. 5.1.3.

Veterinary Premix Dilution, Carryover Control, and Route-Specific Bioburden Limits

Carryover after medicated premix production is quantified by swabbing product-contact surfaces with 10 cm² templates and analysing the active substance by HPLC; acceptance is based on a maximum allowable carryover of 0.5% of the lowest therapeutic dose in the next non-medicated batch. This limit is derived from target animal safety and residue risk. Route-specific bioburden follows Ph. Eur. 5.1.4 for non-sterile oral powders and premixes, but parenteral processing requires additional endotoxin control and aseptic filtration. Storage above 25 °C or relative humidity above 60% can raise moisture content above 1.0%, altering flow, assay, and microbial stability. Opened containers should therefore be resealed with desiccant and consumed within the retest period defined by the stability protocol. Incompatibilities include amine-based additives in wet granulation because residual alkaline excipients can alter the dissolution rate and promote related substance formation.

Published data for this specific configuration is limited in farm drinking-water matrices with heavy biofilm loads; therefore, field trials should measure dispensed concentration at the end of the water line and at drinker height. The multi-route grade should not be interpreted as a finished sterile API or as a farm-ready premix. Each production site must qualify the powder against its own equipment, cleaning validation, and target animal safety file before routine manufacture.